nature neurOSCIenCe a r t I C l e S Neuropathic pain is a major public health problem. Treatment for this disorder has had limited success owing to our incomplete understanding of the mechanisms that underlie the induction of neuropathic pain 1 . Nerve injury-induced neuropathic pain is thought to be triggered by abnormal spontaneous activity that arises in neuromas and first-order sensory neurons of the DRG 2,3 . The abnormal excitability may result from maladaptive changes in gene transcription and translation of receptors, enzymes and voltage-dependent ion channels in the DRG 4 . Voltage-dependent potassium channels govern cell excitability. Peripheral nerve injury downregulates expression of mRNA and protein for these channels in the DRG 5-10 , a phenomenon that may contribute to induction of neuropathic pain [11] [12] [13] [14] . However, the molecular mechanisms that underlie this downregulation are still unknown.
a r t I C l e S Neuropathic pain is a major public health problem. Treatment for this disorder has had limited success owing to our incomplete understanding of the mechanisms that underlie the induction of neuropathic pain 1 . Nerve injury-induced neuropathic pain is thought to be triggered by abnormal spontaneous activity that arises in neuromas and first-order sensory neurons of the DRG 2, 3 . The abnormal excitability may result from maladaptive changes in gene transcription and translation of receptors, enzymes and voltage-dependent ion channels in the DRG 4 . Voltage-dependent potassium channels govern cell excitability. Peripheral nerve injury downregulates expression of mRNA and protein for these channels in the DRG [5] [6] [7] [8] [9] [10] , a phenomenon that may contribute to induction of neuropathic pain [11] [12] [13] [14] . However, the molecular mechanisms that underlie this downregulation are still unknown.
Recent studies suggest that the mechanism for gene regulation involves widespread noncoding RNAs, including lncRNAs [15] [16] [17] . The study of lncRNAs is still in its infancy 18, 19 . A few lncRNAs have been identified in mammalian cells and implicated in gene-regulatory roles such as transcription and translation 18, 19 . Their expression is associated with some physiological and pathological processes, but how they are causally linked to disease development is elusive 18, 19 . Here, we report a new native lncRNA that is expressed in mammalian DRG neurons. Because most of its sequence is complementary to Kcna2 RNA, we named it Kcna2 antisense RNA. We found that Kcna2 antisense RNA may act as a biologically active regulator and participate in induction and maintenance of neuropathic pain by specifically silencing Kcna2 expression in the DRG.
RESULTS

Identification of natural Kcna2 antisense RNA in DRG neurons
To detect Kcna2 antisense RNA, we first searched a database using the complete published Kcna2 cDNA sequence. Although many of the expressed sequence tags reflected portions of Kcna2 transcript, a few were in the antisense direction. Using strand-specific primers for reverse transcription, we identified Kcna2 antisense transcript in the DRGs of rat, mouse, monkey and human (Fig. 1a) , although the sequences were not identical among species. We also detected this transcript in spinal cord, various brain regions and other body organs of rats (Supplementary Fig. 1a ). Using rapid amplification of cDNA ends for directional sequencing of 5′ and 3′ ends, we identified a 2.52-kb Kcna2 antisense RNA in rat DRG ( Supplementary  Fig. 1b) . Most of its sequence overlapped that of Kcna2 RNA, including the coding sequence, the 3′ untranslated region and part of the 5′ untranslated region, but Kcna2 antisense RNA had unique regions at the 5′ and 3′ ends (Fig. 1b) . It had no apparent open reading frame ( Supplementary Fig. 1b) , indicating that Kcna2 antisense RNA is noncoding RNA.
We further confirmed the Kcna2 antisense RNA at the expected size by northern blot analysis of RNA from adult rat DRG and spinal cord, a r t I C l e S although the signals were weak (Fig. 1c) . In situ hybridization histochemistry showed that Kcna2 antisense RNA was expressed weakly in DRG neurons (Fig. 1d) . Approximately 21.5% of DRG neurons (228 of 1,060) were labeled. Most were medium-sized (69%; 25-35 µm in diameter), although some were small (24%; <25 µm in diameter) and a few large (7%; >35 µm in diameter) (Fig. 1e) . Approximately 60.6% of Kcna2 antisense RNA-positive neurons were positive for neurofilament-200 (NF-200) protein, 18.1% for P2X3, 15.3% for isolectin B4 and 28.7% for calcitonin gene-related peptide (CGRP) (Fig. 2) . Although the distribution pattern of Kcna2 antisense RNA partially overlapped that of Kcna2 protein in DRG (Figs. 1e and 3a,b) , most Kcna2 antisense RNA-positive neurons express low amounts of Kcna2 protein (Fig. 3c) .
DRG Kcna2 antisense RNA expression after nerve injury Next, we examined whether expression of DRG Kcna2 antisense RNA is altered in rat after peripheral nerve injury. Consistent with previous studies [5] [6] [7] [8] [9] [10] , unilateral fifth lumbar (L5) spinal nerve ligation (SNL), but not sham surgery, time-dependently downregulated Kcna2 mRNA ( Fig. 4a) and protein ( Fig. 4b) in the ipsilateral L5 DRG. Notably, Kcna2 antisense RNA increased time-dependently in the ipsilateral L5 DRG after SNL (Fig. 4c) . Neither SNL nor sham surgery changed the expression of Kcna2 mRNA, Kcna2 protein or Kcna2 antisense RNA in the ipsilateral L4 DRG (Fig. 4a,c) or L5 spinal cord (n = 4 rats per group per time point, P > 0.05; Supplementary Fig. 2a-c) . Furthermore, the staining density and number of Kcna2 antisense RNA-positive neurons in the ipsilateral L5 DRG were higher than those in the contralateral L5 DRG on days 3, 7 and 14 after SNL (Fig. 4d,e) . These changes occurred predominantly in large DRG neurons (Figs. 1e and 4f) . Results were similar after sciatic nerve axotomy. On day 7 after axotomy, the ratio of ipsilateral to contralateral Kcna2 antisense RNA was 2.2-fold greater in the injured L5 DRG than in that of the sham-operated groups, whereas the corresponding ratio for Kcna2 mRNA was 75% lower (Fig. 4g) . Additionally, Kcna2 protein in the ipsilateral L5 DRG was reduced by 51.8% compared to that in the contralateral L5 DRG from the sham-operated groups (n = 12 per group, P < 0.05; Supplementary Fig. 2d) .
We further examined the opposing SNL-induced changes in Kcna2 antisense RNA and Kcna2 mRNA in individual DRG neurons. Ratios of Kcna2 to Kcna2 antisense RNA were approximately 82, 118 and 121 in small, medium and large DRG neurons, respectively, from sham-operated rats (Fig. 4h) . These ratios decreased, particularly in medium and large DRG neurons, 7 d after SNL (Fig. 4h) . Taken together, these results demonstrate that Kcna2 antisense RNA can be induced in the injured DRG after peripheral nerve injury.
MZF1 promotes Kcna2 antisense RNA gene activity after SNL How is DRG Kcna2 antisense RNA upregulated after nerve injury? Using the online software TFSEARCH, we found a consensus binding motif ( −161 AGTGGGGA −154 ) for the transcriptional activator myeloid zinc finger protein 1 (MZF1) in the promoter region of the Kcna2 Figure 1 Identification and expression of Kcna2 antisense RNA in naive dorsal root ganglion. (a) Native Kcna2 antisense (AS) transcripts detected in the DRGs of rat (Sprague-Dawley), mouse (C57/BL6), monkey (Macaca fascicularis) and human using reverse transcription (RT)-PCR with strand-specific primers. To exclude genomic DNA contamination, we pretreated the extracted RNA samples with excess DNase I. Gapdh is a control. Without RT primers, neither Gapdh nor Kcna2 AS PCR products were detected in DNase I-treated samples, indicating absence of genomic DNA. n = 3 repeated experiments per species. We further confirmed the existence of native Kcna2 AS RNA in the tissues using specific intron-spanning primers. M, 100-bp ladder; C, no-template control. npg a r t I C l e S antisense RNA gene 20, 21 . An electrophoretic mobility shift assay demonstrated binding of MZF1 to this motif in the DRG (Fig. 5a) . A chromatin immunoprecipitation assay revealed that a fragment of the Kcna2 antisense RNA promoter that includes the binding motif could be amplified from the complex immunoprecipitated with MZF1 antibody in nuclear fractions from DRGs in sham-operated rats (Fig. 5b) . This amplification did not occur with normal serum (Fig. 5b) or after preabsorption of MZF1 antibody (data not shown), indicating that the binding of MZF1 to the Kcna2 antisense RNA promoter is specific and selective. SNL increased the binding of MZF1 to the Kcna2 antisense gene promoter, as demonstrated by a 4.12-fold greater band density in the ipsilateral L5 DRG from SNL rats compared to that from sham-operated rats on day 14 (n = 6 rats per group, P < 0.05). This increase may result from SNL-induced time-dependent upregulation of MZF1 in the ipsilateral L5 DRG (Fig. 5c,d ). As expected, neither sham nor SNL surgery altered basal binding activity or MZF1 expression in the contralateral L5 DRG and ipsilateral L4 DRG (data not shown). Moreover, Mzf1 mRNA was expressed with Kcna2 antisense RNA in the DRG neurons (Supplementary Fig. 3a) . These in vivo findings suggest that peripheral nerve injury increases DRG MZF1 expression, allowing the binding of more MZF1 to the promoter region of Kcna2 antisense gene in the injured DRG neurons.
To further examine whether MZF1 directly regulates Kcna2 antisense RNA expression, we overexpressed full-length Mzf1 in cultured human embryonic kidney (HEK)-293T cells ( Supplementary  Fig. 3b,c) , which express endogenous Kcna2 antisense RNA, Kcna2 and other voltage-gated potassium channels. MZF1 overexpression significantly increased Kcna2 antisense RNA and correspondingly decreased Kcna2 mRNA and Kcna2 protein (Fig. 5e,f) . These responses were abolished in cells co-transfected with full-length Mzf1 vector and Mzf1-specific short interfering RNA (but not scrambled Mzf1 siRNA) (Fig. 5e,f and Supplementary Fig. 3d (Fig. 5e,f) . We confirmed MZF1-triggered upregulation of Kcna2 antisense RNA and downregulation of Kcna2 mRNA in cultured DRG neurons that were transduced with recombinant adeno-associated virus 5 (AAV5) that expressed fulllength Mzf1 (Fig. 5g) .
A software prediction showed that the promoter region of the Kcna2 gene does not contain a consensus MZF1-binding motif. MZF1 does not enhance the activity of the Kcna2 gene promoter, but it markedly activates the Kcna2 antisense gene promoter (Fig. 5h) . In naive rats, Kcna2 gene promoter fragments were not amplified from the DRG nuclear complex immunoprecipitated by MZF1 antibody (data not shown). MZF1-triggered downregulation of Kcna2 is thus not likely npg a r t I C l e S to occur by direct binding of MZF1 to the Kcna2 gene promoter. To examine whether Kcna2 antisense RNA mediates this effect, we cloned an AAV5 vector that expresses a Kcna2 sense RNA fragment (−311 to +40). This fragment significantly blocked Kcna2 antisense RNA expression (Fig. 6a,b ) but did not alter basal expression of Kcna2 mRNA or Kcna2 protein or produce truncated Kcna2 protein in cultured HEK-293T cells or DRG neurons (Fig. 6a,b) . We found that the Kcna2 sense fragment blocked the MZF1-induced increase in Kcna2 antisense RNA and reversed the MZF1-induced reduction in Kcna2 mRNA in DRG neurons (Fig. 5g) (Fig. 6a,b) . Then we injected AAV5-Kcna2 antisense or AAV5-EGFP unilaterally into the L4 and L5 (L4/5) DRGs. Four weeks after injection, EGFP-labeled AAV5 was limited to the ipsilateral L4/5 DRG neurons and their fibers and terminals ( Supplementary Fig. 4a−g ). Approximately 87.1% of labeled cells were positive for NF-200, 4.21% for substance P, 6.32% for CGRP and 10.0% for P2X3 (Supplementary Fig. 4h ), a distribution similar to that of Kcna2 antisense RNA-positive neurons in the injured DRG after SNL (Fig. 4f) . Expression of the Kcna2 antisense RNA was significantly increased in the L4/5 DRGs at 4 weeks, reached a peak at 8 weeks and remained high for at least 12 weeks after viral injection (Fig. 6c) . In contrast, the expression of Kcna2 mRNA and protein was significantly and temporally reduced in the ipsilateral L4/5 DRGs (Fig. 6c-e) . The amounts of mRNA and protein of Kcna1, Kcna4 or Scn10a were unaffected (Fig. 6c-e) . These results indicate that Kcna2 antisense RNA specifically and selectively targets Kcna2. Using a voltage-clamp technique, we recorded Kcna2-related current in neurons freshly dissociated from the injected L4/5 DRGs 8-12 weeks after injection. To increase the recording efficiency, we injected AAV5-EGFP alone (control group) or a mixed viral solution of AAV5-Kcna2 antisense plus AAV5-EGFP (Kcna2 antisense-treated group) and recorded only green DRG neurons (Fig. 7a) . In the Kcna2 antisense-treated group, total voltage-gated potassium current density was significantly lower in large-and medium-diameter neurons (Fig. 7a,b and Supplementary Fig. 5a−c) . To verify whether this reduction was due to Kcna2 downregulation, we used bath application of 100 nM maurotoxin (MTX), a selective Kcna2 current inhibitor [22] [23] [24] . MTX produced greater reductions in total voltage-gated potassium current in large (n = 14 per group) and medium (control: n = 17; antisense, n = 15) neurons from the control group than in those from the Kcna2 antisense-treated group at depolarized voltages (P < 0.05 or 0.01; Fig. 7a,b and Supplementary Fig. 5a−c) . When tested at +50 mV, large and medium neurons in the control group retained 81.7 ± 1.7% and 85.1 ± 2.2% of current, respectively, after MTX treatment, but large and medium neurons from the Kcna2 antisensetreated group retained 92.3 ± 0.9% and 94.9 ± 1.6% of current, a r t I C l e S respectively. In small DRG neurons, the current reduction by MTX was less prominent, but the difference between control and Kcna2 antisense-treated groups was still significant (n = 11 neurons per group, P < 0.05; Supplementary Fig. 5d−f) . These data indicate that Kcna2 antisense RNA reduces total voltage-gated potassium current densities in large and medium DRG neurons and decreases Kcna2-related current in all DRG neurons. To assess whether Kcna2 antisense RNA modulates DRG neuronal excitability, we carried out whole-cell current-clamp recording 8-12 weeks after injection. Compared to the control group, Kcna2 antisense RNA treatment significantly increased resting membrane potentials, by 6.74 mV and 10.52 mV in large and medium neurons, respectively (Fig. 7c) , and reduced current thresholds by 217 pA and 344 pA, respectively (P < 0.01; Fig. 7d) . The average number of action potentials evoked by stimulation of ≥300 pA in the Kcna2 antisense-treated group was greater than the average number evoked by the corresponding stimulation intensity in the control group in large and medium neurons (Fig. 7e-g ). No such changes were observed in small DRG neurons (Fig. 7c,d,h ). There were no apparent differences between the two groups in membrane input resistances or other action potential parameters, such as amplitude, threshold, duration, overshoot and after-hyperpolarization amplitude (Supplementary Table 1 ). Application of MTX into DRG neurons produced similar effects (Supplementary Fig. 6 and Supplementary Table 1). Our findings indicate that Kcna2 knockdown or current inhibition increases DRG neuronal excitability.
Lastly, we examined whether rats that received L4/5 DRG injections of Kcna2 antisense RNA showed behavioral changes in nociceptive thresholds. Injection of AAV5-Kcna2 antisense, but not of AAV5-EGFP, produced mechanical and cold hypersensitivities as demonstrated by ipsilateral decreases in paw withdrawal threshold and paw withdrawal latency, respectively (n = 14 rats per group, P < 0.01; Fig. 7i ). These hypersensitivities developed by 4 to 6 weeks, reached a peak at 8 weeks and were maintained for at least 12 weeks (Fig. 7i) . Neither AAV5-Kcna2 antisense nor AAV5-EGFP affected locomotor functions (data not shown). These findings suggest that Kcna2 antisense RNA-triggered DRG Kcna2 downregulation induces mechanical and cold hypersensitivities, two main clinical symptoms of neuropathic pain.
Blocking DRG Kcna2 antisense RNA attenuates neuropathic pain Finally, we inquired whether blocking nerve injury-induced upregulation of DRG Kcna2 antisense RNA would affect reductions in DRG Kcna2 expression and nociceptive thresholds after nerve injury. Consistent with our in vitro work (Fig. 6a,b) , in vivo DRG injection of AAV5-Kcna2 sense fragment, but not AAV5-EGFP, significantly blocked upregulation of Kcna2 antisense RNA and downregulation of Kcna2 mRNA and protein in the injured DRGs after SNL or chronic constriction injury (CCI) (Fig. 8a,b) . These effects occurred at 4 weeks and were maintained for at least 12 weeks after viral injection. Injection of AAV5-Kcna2 sense fragment alone did not alter basal expression of Kcna2 mRNA and Kcna2 protein or Kcna2 antisense RNA in the ipsilateral L5 DRG of sham-operated rats (Fig. 8a,b) . To examine the role of Kcna2 antisense RNA in neuropathic pain induction, we subjected rats to SNL 4 weeks after DRG viral injection, as our pilot work showed that there was too little Kcna2 sense fragment to block SNL-induced Kcna2 antisense RNA expression before that time. SNL produced mechanical, cold and thermal hypersensitivities on npg a r t I C l e S the ipsilateral side in the EGFP-injected group (Fig. 8c) . By contrast, hypersensitivity was attenuated in the Kcna2 sense fragment-injected rats (Fig. 8c) . Paw withdrawal threshold to mechanical stimulation and paw withdrawal latency to cold and thermal stimuli were higher in the Kcna2 sense fragment-injected rats than in the EGFP-injected group from days 3 to 14 after SNL (Fig. 8c) . We observed similar effects of AAV5-Kcna2 sense fragment on neuropathic pain development in the CCI model as well (Fig. 8d) .
To further investigate the role of Kcna2 antisense RNA in neuropathic pain maintenance, we subjected rats to SNL 2 weeks after DRG viral injection. Mechanical, cold and thermal hypersensitivities were completely developed in both the Kcna2 sense fragment-injected and EGFP-injected rats on day 7 after SNL (Fig. 8e) . These hypersensitivities were markedly attenuated on days 14, 21 and 28 after SNL in the Kcna2 sense fragment-injected rats (Fig. 8e) . Neither AAV5-Kcna2 sense fragment nor AAV5-EGFP affected paw withdrawal threshold or latency on the contralateral side (Fig. 8c-e) , affected locomotor function (data not shown) or altered basal responses to mechanical or cold stimuli in sham-operated rats (data not shown). Our findings indicate that Kcna2 antisense RNA contributes to neuropathic pain development and maintenance and that blocking its expression may have clinical applications in neuropathic pain treatment.
DISCUSSION lncRNAs were recently shown to occur naturally in mammals 18, 19 . They can be transcribed in cis from the opposing DNA strands of the RNA genes at the same genomic locus or in trans from a locus different from that of the RNA genes 25 . Rat Kcna2 antisense RNA is more than 2.5 kb and complementary to most of the Kcna2 RNA sequence, strongly suggesting that Kcna2 antisense RNA is a cisencoded lncRNA. Of note, the Kcna2 antisense RNA exhibits the same splicing patterns as the Kcna2 sense RNA. Because the splice junctions of the Kcna2 sense gene are canonical (that is, they follow the GT-AG rule), splicing mechanisms of the Kcna2 antisense gene are unusual and merit further investigation.
Expression of native Kcna2 antisense RNA, like that of the mRNA, can be regulated by transcriptional activation. Nerve injury-induced upregulation of Kcna2 antisense RNA was triggered through DRG MZF1 activation. Whether other transcription factors also trigger activation of Kcna2 antisense transcription is unknown. Additionally, the increase in antisense RNA might be caused by increases in RNA stability and/or other epigenetic modification. These possibilities cannot be excluded and will be addressed in our future studies.
Kcna2 antisense RNA functions as a biologically active regulator of Kcna2 mRNA in primary afferent neurons. Normally, Kcna2 antisense RNA was expressed at a low level in a few (mostly mediumsized) DRG neurons, whereas Kcna2 protein was highly expressed in most medium-or large-sized DRG neurons 9 . Of note, injury to the peripheral nerve not only increased Kcna2 antisense RNA expression but also altered its subpopulation distribution pattern to large-and medium-sized neurons in the injured DRG. Conversely, Kcna2 mRNA and Kcna2 protein were correspondingly downregulated in these neurons [5] [6] [7] [8] [9] [10] . This downregulation is likely caused by the increase in Kcna2 antisense RNA, as overexpression of Kcna2 antisense RNA in cultured HEK-293T cells or DRG neurons selectively and specifically inhibited Kcna2 mRNA and protein expression. This effect may be related to the extensive overlap of their complementary regions, including the transcription and translation initiation sites. DRG Kcna subunits are functional heteromultimers 9, [26] [27] [28] . The expression of other Kcna subunits was unaffected, likely because they lack complementary sequences and the inhibitory effect of Kcna2 antisense RNA occurs before the formation of heteromultimers. However, the fact that Kcna2 downregulation markedly reduced total voltage-gated potassium current density in large and medium DRG neurons indicates that Kcna2 is a key subunit in determining voltage-gated potassium channel function in these neurons. Minimal reduction was observed in small DRG neurons, possibly because Kcna2 is poorly expressed in those neurons 9 .
We found that selective reduction of Kcna2 expression in DRG by Kcna2 antisense RNA decreased total voltage-gated potassium current, depolarized the resting membrane potential, decreased current threshold for activation of action potentials and increased the number of action potentials in large and medium DRG neurons. Depolarization of DRG neuronal resting membrane potential by DRG Kcna2 downregulation was also reported previously 29, 30 . Kcna2 antisense RNA did not affect action potential threshold or amplitude in DRG neurons, as these two parameters may be determined predominantly by Na + channels. Kcna2 knockdown by Kcna2 antisense RNA produced a modest, but insignificant, increase in DRG neuronal membrane input resistances, an observation that is consistent with the fact that membrane input resistance also depends on other voltage-gated potassium channels (for example, Kcna1, Kcna4), hyperpolarization-activated cyclic nucleotidegated channels 31, 32 and chloride channels 33 expressed on DRG neuronal membrane. In addition, the depolarized resting membrane potential by itself may increase resting potassium conductance 31, 32 , which may counteract Kcna2 deficiency-induced increase in membrane input resistance. The increase in membrane input resistance caused by blocking voltage-gated potassium current in DRG neurons was observed only in the absence of a significant resting membrane potential depolarization 34 . The fact membrane input resistance is unchanged but that resting membrane potentials are markedly depolarized in DRG neurons has been reported after peripheral nerve injury 35 .
Nerve injury-induced increases in spontaneous ectopic activity, which have been found primarily in injured myelinated afferents and the corresponding large and medium DRG neuronal bodies 36, 37 , are considered to play a leading role in the genesis of neuropathic pain 1, 3 . Peripheral nerve injury increased Kcna2 antisense RNA mainly in medium and large DRG neurons. Kcna2 antisense RNA-induced depolarization of the resting membrane potential of DRG neurons may render those neurons more prone to hyperexcitability. Indeed, animals that overexpressed Kcna2 antisense RNA exhibited significant hypersensitivities to mechanical and noxious cold stimuli. Substance P and CGRP in the injured myelinated fibers and in large and medium DRG neurons are markedly increased as early as 2 d after nerve injury 3, 38 . It is very likely that the increase in excitability of large and medium DRG neurons drives the release of these neurotransmitters from their primary afferent terminals and leads to spinal central sensitization, which contributes to the development and maintenance of neuropathic pain. This conclusion is supported by the fact that blocking SNL-evoked upregulation of Kcna2 antisense RNA reversed the reduction in DRG Kcna2 and attenuated induction and maintenance of nerve injury-induced mechanical and cold hypersensitivities. It is still a puzzle how blocking SNL-induced downregulation of DRG Kcna2 almost abolishes SNL-induced pain hypersensitivity at the late time points. We think that blocking DRG Kcna2 downregulation causes persistent reduction in DRG excitability that may enhance the decrease in primary afferent transmitter release, resulting in attenuation of spinal central sensitization formation. Persistent reduction in DRG neuronal excitability may also block further SNL-induced changes in the expression of other DRG genes, including transcription factors that govern gene expression. This activity could create positive feedback to further reduce DRG excitability. a r t I C l e S These potential mechanisms remain to be confirmed. Taken together, our findings suggest that Kcna2 antisense RNA is an endogenous trigger in neuropathic pain development and maintenance. Regulation of Kcna2 channel expression may be a target for treating neuropathic pain.
In summary, identification of Kcna2 antisense RNA may point to regulation of Kcna2 channel expression and neuronal excitability, a novel mechanism in neuropathic pain, and potential targets for the development of therapies of this disorder. Because Kcna2 antisense RNA, Kcna2 mRNA and Kcna2 protein are expressed broadly, they may be implicated in other pathological processes. In addition, demonstration of Kcna2 antisense RNA may challenge current molecular methodologies. For example, we cannot use sense probes usually designed as negative controls, as they detect endogenous antisense RNAs in in situ hybridization, or oligo(dT) primers, as they allow reverse transcription of both sense and antisense RNAs. Therefore, our findings not only provide conceptual advances regarding the development of neuropathic pain but also will affect the conduct of research in other fields.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Animals. Male Sprague-Dawley rats weighing 200-250 g were kept in a standard 12-h light/dark cycle, with water and food pellets available ad libitum. All procedures used were approved by the Animal Care and Use Committee at the Johns Hopkins University and consistent with the ethical guidelines of the US National Institutes of Health and the International Association for the Study of Pain. All efforts were made to minimize animal suffering and to reduce the number of animals used. All of the experimenters were blind to treatment condition. nerve injury models. L5 spinal nerve ligation (SNL) [39] [40] [41] , chronic constriction injury (CCI) 42 and sciatic nerve axotomy 39 models of neuropathic pain were carried out as described previously. Sham-operated groups underwent identical procedures but without transection of the respective nerve.
Behavioral analysis. Mechanical, cold, thermal and locomotor behavioral tests were carried out. Each behavioral test was carried out at 1-h intervals. Paw withdrawal thresholds in response to mechanical stimuli were first measured with the up-down testing paradigm as described previously 39 . Paw withdrawal latencies to noxious cold (0 °C) were then measured with a cold plate, the temperature of which was monitored continuously. Each animal was placed in a Plexiglas chamber on the cold plate, which was set at 0 °C. The length of time between the placement of the hind paw on the plate and the animal jumping, with or without paw licking and flinching, was defined as the paw withdrawal latency. Each trial was repeated three times at 10-min intervals for the paw on the ipsilateral side. A cutoff time of 60 s was used to avoid tissue damage. Finally, paw withdrawal latencies to noxious heat were measured with Model 336 Analgesia Meter (IITC Inc./Life Science Instruments, Woodland Hills, CA, USA) as described previously 41 . Tests of locomotor function, including placing, grasping and righting reflexes, were performed before and after viral injection according to previously described protocols 39, 40, 43 .
cell line culture and transfection. HEK-293T cells were cultured in Dulbecco's modified Eagle's medium at 37 °C in a humidified incubator with 5% CO 2 . The plasmids were transfected into the HEK-293T cells with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. dRg neuronal culture and AAV5 transduction. Adult male rats were put to death with isoflurane. DRGs were collected in cold DH10 (90% DMEM/F-12 (Gibco, Grand Island, NY), 10% FBS (JR Scientific, Woodland, CA), 1% penicillin-streptomycin (Quality Biological, Gaithersburg, MD)) and then treated with enzyme solution (3.5 mg/ml dispase, 1.6 mg/ml collagenase type I in HBSS without Ca 2+ and Mg 2+ (Gibco)) at 37 °C. After the centrifugation, dissociated cells were resuspended in DH10 and plated at a density of 1.5 × 10 5 to 4 × 10 5 cells on glass coverslips or in a six-well plate coated with poly-l-lysine (0.5 mg/ml, Sigma, St. Louis, MO) and laminin (10 µg/ml, Invitrogen). The cells were incubated in 5% CO 2 at 37 °C. One day later, 1 µl of AAV5 virus (titer ≥1 × 10 12 /ml) was added to each well. Cells were collected 4 d later.
Reverse transcription (RT)-PcR, rapid amplification of cdnA ends (RAce) and quantitative RT-PcR. Total RNA was extracted by the Trizol method (Invitrogen) and treated with excess DNase I (New England Biolabs, Ipswich, MA). Highly purified, DNase-treated RNA samples from human DRG were purchased from Clontech Laboratories, Inc. (Mountain View, CA). Using the Omniscript RT kit (QIAGEN, Valencia, CA) with strand-specific primers, we reverse transcribed single-stranded cDNA from RNA (1 µg). RT and PCR primers were determined from the UCSC genome database (Supplementary Table 2 ). Template (1 µl) was amplified by PCR with TaKaRa Taq DNA polymerase (Clontech Laboratories, Inc.) in 20 µl total reaction volume containing 0.5 µM of PCR primer. PCR amplification consisted of 30 s at 94 °C, 20 s at 56 °C, and 20 s at 72 °C for 35 cycles.
RNA fragments amplified from the rat DRG were extended first by using RT-PCR with strand-specific primers and then by using a RACE kit (2nd Generation, Roche Diagnostics, Indianapolis, IN). The 5′ RACE was used for amplification of the 5′-end of cDNA according to the manufacturer's instructions. The 3′ RACE analysis was performed by ligating an adaptor to the 3-hydroxyl group of the RNA, followed by gene-and adaptor-specific amplification.
All primers are listed in Supplementary Table 2. PCR products from RT-PCR, 5′ RACE and 3′ RACE were extracted, purified and verified by automated DNA sequencing. All sequences were analyzed and the full-length Kcna2 antisense RNA sequence determined.
For quantitative real-time RT-PCR, three DRGs from three individual rats were pooled to provide enough RNA. cDNA was prepared as described above. Template (1 µl) was amplified by real-time PCR by using 1 µM of each probe and 0.5 µM of each primer listed in Supplementary Table 2. Each sample was run in quadruplicate in a 20-µl reaction with the TaqMan Universal PCR master mix kit (Applied Biosystems, Grand Island, NY). Reactions were performed in 96-well plates in an ABI 7500 Fast real-time PCR system (Applied Biosystems). Ratios of ipsilateral mRNA to contralateral mRNA were calculated by using the ∆Ct method (2 −∆∆Ct ) at a threshold of 0.02, as our pilot data indicated that the amplification reactions of the target genes and reference genes have similar PCR efficiency (Supplementary Fig. 8a ). All data were normalized to Gapdh, which was demonstrated to be stable after SNL (Supplementary Fig. 8b−d) .
For single-cell quantitative RT-PCR, freshly dissociated rat DRG neurons were first prepared as described below. Four hours after plating, small, medium and large DRG neurons were randomly collected under an inverted microscope fit with a micromanipulator and microinjector. A single living neuron was selected with a glass micropipette, without contamination by other neurons, and placed in a PCR tube with 6 µl of cell lysis buffer (Signosis, Sunnyvale, CA) as described 44 . After centrifugation, the supernatants were collected. The remaining real-time RT-PCR procedure was carried out as described 44 or according to the manufacturer's instructions with the single-cell real-time RT-PCR assay kit (Signosis).
rAAV5 plasmid constructs and virus production. After RNA was extracted from the DRG, full-length Kcna2 antisense cDNA, full-length Mzf1 cDNA and Kcna2 sense cDNA fragment (−311 to +40) were amplified by nested RT-PCR (primers in Supplementary Table 2) . Restriction enzyme recognition sites were introduced at the 5′ and 3′ ends of the three fragments. The PCR products were cloned by using the pGEM-T easy cloning kit (Invitrogen). The positive clones were identified by restriction enzyme analysis (BspEI/NotI) and clone sequencing.
The identified fragments were ligated into the BspEI/NotI sites of the proviral plasmids (University of North Carolina, Chapel Hill) to replace enhanced GFP (EGFP) and the S-D sequence. The resulting four vectors expressed EGFP, Kcna2 antisense RNA, Kcna2 sense fragment and MZF1 under the control of the cytomegalovirus promoter. rAAV5 viral particles carrying the four cDNAs were produced at the University of North Carolina Vector Core. northern blotting. To prepare complementary RNA (cRNA) probes of rat Kcna2 antisense RNA, we constructed the pSC-A plasmid, which contained a 0.946-kb DNA template, and identified the sequence using double-strand DNA sequencing. The plasmid construct was linearized by Acc65I and XhoI. A riboprobe was generated from in vitro transcription and labeled with 32 P-dUTP.
Northern blot analysis was performed as described previously 45 . The extracted RNA (10 µg) was separated on a 1.5% agarose/formaldehyde gel, transferred to a BrightStar-plus positively charged nylon membrane and cross-linked by using ultraviolet light. After prehybridization, the membrane was hybridized overnight at 68 °C with 32 P-dUTP-labeled cRNA probes for Kcna2 antisense RNA. After the membrane was washed and dried, autoradiography was carried out.
In situ hybridization histochemistry. In situ hybridization histochemistry was carried out as described previously with minor modification 46, 47 . Two sets of 20-µm sections were collected from each DRG by grouping every third section. Kcna2 cRNA probe (0.268-kb fragment) and GFP cRNA probe (0.187-kb fragment) were prepared by in vitro transcription and labeled with digoxigenin-dUTP according to the manufacturer's instructions (Roche Diagnostics, Indianapolis, IN). After treatment with proteinase K and prehybridization, the two sets of sections were hybridized with digoxigenin-dUTP-labeled cRNA probes for Kcna2 antisense RNA and GFP RNA for 18 h at 68 °C. After being washed, the sections were incubated with alkaline phosphatase-conjugated anti-digoxigenin. The signals were developed with 5-bromo-4-chloro-3′-indolyl phosphate p-toluidine salt and nitro-blue tetrazolium chloride substrates. For the double labeling of in situ hybridization histochemistry and immunohistochemistry, the sections were treated as described above except that they were hybridized only with npg dRg microinjection. DRG microinjection was carried out as described 51, 52 . Briefly, a midline incision was made in the lower lumbar back region and the L5 vertebral body was exposed. After the lamina was removed and the DRG exposed, viral solution (2 µl) was injected into two sites in the L4 and L5 DRGs or into one site in the L5 DRG with a glass micropipette connected to a Hamilton syringe. The pipette was removed after 10 min. After injection, the skin incision was closed with wound clips. The injected rats showed no signs of paresis or other abnormalities. The injected DRGs, stained with hematoxylin and eosin, retained their structural integrity and contained no visible leukocytes. The immune responses from viral injection were therefore minimal.
Statistical analysis. For in vitro experiments, the cells were evenly suspended and then randomly distributed in each well tested. For in vivo experiments, the animals were distributed into various treated groups randomly. All of the results are given as means ± s.e.m. Data distribution was assumed to be normal, but this was not formally tested. The data were statistically analyzed with two-tailed, paired or unpaired Student's t-test and a one-way or two-way ANOVA. When ANOVA showed significant difference, pairwise comparisons between means were tested by the post hoc Tukey method (SigmaStat, San Jose, CA). No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported previously in the fields [39] [40] [41] . Significance was set at P < 0.05.
